Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty
Public ClinicalTrials.gov record NCT07138898. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to assess the incidence of rheumatologic flares, changes in pain scores (VAS), changes in functional outcomes (PROMIS), wound complications, surgical site infections, and return trips to the operating room for rheumatology patients following shoulder replacements, comparing those who stop their immunosuppressants preoperatively for the same amount of time as suggested in the literature for hip and knee arthroplasty versus those who hold the medications for a shorter period of time preoperatively.
Study identification
- NCT ID
- NCT07138898
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 80 participants
Conditions and interventions
Conditions
Interventions
- Methotrexate Drug
- Sulfasalazine Drug
- Hydroxychloroquine Drug
- Leflunomide Drug
- Azathioprine Drug
- Mycophenolate Drug
- Cyclosporine Drug
- Tacrolimus Drug
- Etanercept Drug
- Adalimumab Drug
- Golimumab Drug
- Certolizumab Drug
- Infliximab Drug
- Rituximab Biological
- Belimumab Biological
- Tocilizumab Biological
- Anakinra Biological
- Canakinumab Biological
- Abatacept Biological
- Secukinumab Biological
- Ixekizumab Biological
- Bimekizumab Biological
- Ustekinumab Biological
- Guselkumab Biological
- Risankizumab Biological
- Tofacitinib Drug
- Upadacitinib Drug
Drug · Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 11, 2025
- Primary completion
- Dec 31, 2027
- Completion
- Dec 31, 2027
- Last update posted
- Jul 8, 2026
2025 – 2028
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| NYU Langone Health | New York | New York | 10016 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07138898, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 8, 2026 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07138898 live on ClinicalTrials.gov.